Resources · Medicines & Infection
The microbes and the medicines.
The microbiology behind chest infections, and the main medicines used in heart and lung disease. Using an inhaler? Start with technique. Checking what's in it? Inhalers by ingredient.
Cardiorespiratory Physiotherapy
Medicines & Infection · area 04 of 07
Outcome Measures & Clinical Skills
Bugs & infection
Microbiology & Infection
The microbes behind chest infections and why they matter.
FoundationMicrobiology & InfectionThe bugs behind chest infections and why they matter.InfectionPseudomonas aeruginosaEradication, chronic infection and cross-infection in bronchiectasis and CF.InfectionBurkholderia cepacia complexCepacia syndrome, segregation and transplant eligibility.InfectionMRSA & Staphylococcus aureusWhen to treat, when to eradicate, and what the evidence will not yet say.InfectionNon-Tuberculous Mycobacteria (NTM)M. avium and related slow-growing lung infections.
Medicines & how they work
Medications
A physiotherapist-focused reference to the main medicines in heart and lung disease.
Start hereMedications OverviewDrug classes and how they affect a physiotherapy session.InhaledInhaled MedicationDevice types, drug classes and technique points.InhaledInhalers by IngredientEvery inhaler by what is actually in it — ingredient fingerprint, device code, and the duplicate-ingredient check.InhaledAsthma Treatment LevelsTwo reliever strategies, four levels, and the technique-and-adherence gate before every step up.SystemicSteroids (Corticosteroids)Inhaled preventers and oral steroid courses.AcuteAntibioticsOral and IV antibiotics in respiratory infection.AcuteHow GPs Prescribe in a COPD ExacerbationThe primary care algorithm, and the four points where a physiotherapist changes the outcome.AdjunctNebulised & Mucoactive TherapyMucoactive and airway-clearance adjunct agents.AdjunctOxygen TherapyOxygen as a prescribed drug, delivery devices and humidification.SpecialistBiologics in Respiratory DiseaseTargeted therapy beyond salbutamol and oral steroids — client guide and clinical evidence.ComorbidityGLP-1 and Dual GIP/GLP-1 Receptor AgonistsMechanism, indications, dose escalation, trial evidence and discontinuation data.EmergingThe Cystic Fibrosis Drug PipelineFrom airway clearance and antibiotics to CFTR modulators — and the RNA and gene therapies in trials now.EmergingThe IPF Drug PipelineFrom the harm of immunosuppression to two antifibrotics — and the PDE4B inhibitors now in phase 3.
No resources found
Try a different search term.
These resources are for general education and are not a substitute for individualised assessment by a qualified clinician. If your symptoms change suddenly or severely, seek urgent medical care.